Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?
by Zacks Equity Research
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.
Diabetes Management Gains FDA Attention: 3 Stocks in Focus
by Sriparna Ghosal
The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Abbott (ABT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 Dividend ETFs That Offer Growth in 2020
by Sweta Killa
In a low interest rate environment, dividend investing has been the hot spot and seems an excellent choice for 2020.
Abbott's Less-Invasive Surgery for Heart Pump Gets FDA Nod
by Zacks Equity Research
Abbott's (ABT) less invasive approach for heart surgery for its heart pump gets the FDA clearance, thus paving the way for avoiding open heart surgeries.
The Zacks Analyst Blog Highlights: AbbVie, Abbott Labs, Allergan, Johnson & Johnson and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Abbott Labs, Allergan, Johnson & Johnson and Merck
The Zacks Analyst Blog Highlights: Facebook, Alibaba, Mastercard, Abbott Laboratories and Philip Morris International
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Alibaba, Mastercard, Abbott Laboratories and Philip Morris International
3 Dividend-Paying Large Cap Pharma Stocks to Consider for 2020
by Christopher Vargas
The stock market continued its end of the year rally Friday as the three major indices all hit new intraday highs.
Top Stock Reports for Facebook, Alibaba & Mastercard
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Alibaba Group (BABA) and Mastercard (MA).
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $86.93, marking a -0.15% move from the previous day.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $83.87, moving -1.88% from the previous trading session.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $84.51 in the latest trading session, marking a -1.1% move from the prior day.
Digital Diabetes Management Gains Momentum: 3 Stocks in Focus
by Trina Mukherjee
With digital diabetes management space rapidly gaining momentum, patients with diabetes can look forward to better and improved outcomes.
The Zacks Analyst Blog Highlights: Abbott, Philip Morris, Lowe's, Equinix and Kinder Morgan
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott, Philip Morris, Lowe's, Equinix and Kinder Morgan
Top Analyst Reports for Abbott, Philip Morris & Lowe's
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), Philip Morris International (PM) and Lowe's Companies (LOW).
Abbott (ABT) Up 2.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medical Products' Nov 7 Earnings Roster: ABC, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Medical Instruments' Oct 31 Earnings Roster: IDXX, ABMD & More
by Urmimala Biswas
Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.
Medical Products' Oct 30 Earnings Roster: MCK, MASI & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.
Medical Products' Oct 24 Earnings Roster: BAX, CERN & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Here's Why You Should Hold on to Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Abbott's (ABT) performance.
Medical Products' Earnings Roster for Oct 23: TMO, BSX & More
by Zacks Equity Research
Encouraging growth in the emerging markets despite the ongoing trade tiff is likely to contribute to revenues in the medical products space this earnings season.
Medical Products Industry Outlook: Prospects Seem Promising
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.